Granules India gets USFDA nod for Losartan Potassium & Hydrochlorothiazide Tablets

Granules India Limited announced that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Losartan Potassium and Hydrochlorothiazide Tablets USP, 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg. 

 

It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Hyzaar Tablets of Organon LLC, the company said.

 

Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension to lower blood pressure and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy. 

 

Now, as per the regulatory filing, Granules have a total of 60 ANDA approvals from US FDA (58 Final approvals and 2 tentative approvals). 

 

The current annual U.S. market for Losartan and Hydrochlorothiazide Tablets is approximately $73 Million, according to MAT Jul 2023, IQVIA/IMS Health.

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Candlestick Patterns

blog-logo

11 mins read . 03 Oct 2024

Ascending Triangle Pattern - Definition, Tips, Component & How to Trade

  • 0 people read
blog-logo

IPO

blog-logo

5 mins read . 19 Sep 2024

Vision Infra Equipment Solutions Limited IPO

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions